Alexza Pharmaceuticals announces two promotions

Alexza Pharmaceuticals has promoted Catherine McAuliffe to VP, Operations and Stacy Palermini to VP, Finance, the company said. McAuliffe most recently served as Executive Director, Operations; the position of VP, Operations is newly created. Palermini was previously Executive Director, Finance.

Alexza is developing several products using its Staccato inhalation platform, including Staccato alprazolam for the treatment of seizures and Staccato zaleplon for insomnia. Adasuve Staccato loxapine is marketed by Teva in the US and by Ferrer in Europe.

The company recently announced that it was considering a number of strategic options, including selling corporate assets or a strategic business combination.

Read the Alexza press release.